Clinical trials under way with COVID-19 convalescents

HAVANA, Cuba, Jul 7 (ACN) The Center for Molecular Immunology (CIM) is conducting two clinical trials—named CORVAXCIM and COREPOCIM—on COVID-19 convalescents, according to Sc.D. Mayra Ramos Suzarte, head of CIM’s clinical trials department, who explained that the first of these studies evaluates the safety and effects of the CIMAvax-EGF lung cancer vaccine in convalescents with respiratory disorders after infection by SARS-CoV-2.

“This is a multi-center controlled, open, randomized, phase II trial divided into two groups: one is administered the vaccine and the best established standard therapy for respiratory sequelae, and the other receives only the treatment,” she remarked. “By giving them eight doses over six months, our researchers expect to halt the progression of or prevent the pulmonary fibrosis caused by the disease.”

The trial is expected to include 135 people, but there may be more if the Ethics Commissions approve the extension of the study to all Cuban provinces.